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Abstract
Objective To evaluate the impact of a diet and physical activity
intervention (BeWEL) on weight change in people with a body mass
index >25 weight (kg)/height (m)2 at increased risk of colorectal cancer
and other obesity related comorbidities.
Design Multicentre, parallel group, randomised controlled trial.
Setting Four Scottish National Health Service health boards.
Participants 329 overweight or obese adults (aged 50 to 74 years) who
had undergone colonoscopy after a positive faecal occult blood test
result, as part of the national bowel screening programme, and had a
diagnosis of adenoma confirmed by histopathology. 163 were randomised
to intervention and 166 to control.
Intervention Participants were randomised to a control group (weight
loss booklet only) or 12 month intervention group (three face to face
visits with a lifestyle counsellor plus monthly 15 minute telephone calls).
A goal of 7% reduction in body weight was set and participants received
a personalised energy prescription (2508 kJ (600 kcal) below that
required for weight maintenance) and bodyweight scales. Motivational
interviewing techniques explored self assessed confidence, ambivalence,
and personal values concerning weight. Behavioural strategies included
goal setting, identifying intentions of implementation, self monitoring of
body weight, and counsellor feedback about reported diet, physical
activity, and weight change.
Main outcome measures The primary outcome was weight change
over 12 months. Secondary outcomes included changes in waist
circumference, blood pressure, fasting cardiovascular biomarkers, and
glucose metabolism variables, physical activity, diet, and alcohol
consumption.
Results At 12 months, data on the primary outcome were available for
148 (91%) participants in the intervention group and 157 (95%) in the
control group. Mean weight loss was 3.50 kg (SD 4.91) (95% confidence
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interval 2.70 to 4.30) in the intervention group compared with 0.78 kg
(SD 3.77) (0.19 to 1.38) in the control group. The group difference was
2.69 kg (95% confidence interval 1.70 to 3.67). Differences between
groups were significant for waist circumference, body mass index, blood
pressure, blood glucose level, diet, and physical activity. No reported
adverse events were considered to be related to trial participation.
Conclusions Significant weight loss can be achieved by a diet and
physical activity intervention initiated within a national colorectal cancer
screening programme, offering considerable potential for risk reduction
of disease in older adults.
Trial registration Current Controlled Trials ISRCTN53033856.
Introduction
Colorectal cancer is the third most common cancer and cause
of cancer related death in the United Kingdom.1 Most cases
(95%) occur in people aged over 50, who often have other
lifestyle related comorbidities, such as obesity, type 2 diabetes
mellitus, and cardiovascular disease.2 3 These diseases share
common risk factors, including increased waist circumference,
altered glucose metabolism, and abnormal lipid levels.4 5
Consistent with findings for cardiovascular disease and type 2
diabetes mellitus,6 7 high levels of body fat (body mass index
>23 (weight (kg)/height (m)2)) or a large waist circumference
are associated with an increased risk of cancer.8 Recent UK
estimates on cancer preventability indicate that 12% of colorectal
cancers could be prevented by increased physical activity, 14%
by the avoidance of excess weight, and 34% by changes in diet
and alcohol intake.9 Thus several modifiable risk factors can be
identified and tackled with potential benefit to risk of colorectal
cancer, and proved benefit on risk reduction of type 2 diabetes
mellitus and cardiovascular disease.
The general public perceive health professionals as experts in
matters relating to disease prevention and management. Thus,
individual communications with patients on behaviour change
can help to endorse the messages of public health campaigns.
The National Health Service colorectal cancer screening
programme10 is increasing the identification of adenomas and
offers a timely opportunity for expert health professionals to
offer advice on risk factor reduction to older, overweight adults
who had an adenoma to minimise the risk of colorectal cancer
and other obesity related comorbidities. Surveillance
colonoscopy is offered to patients who have had adenomas, but
procedures may still miss adenomas, and several studies have
reported interval cancers diagnosed between examinations.11 12
Current evidence suggests that the risk of new adenomas is
around 40% after three years, although this may be higher in
obese men.13 A Japanese study of 16 500 people found a
significant reduction in adenoma recurrence in those who had
lost weight in the follow-up period compared with those who
maintained or gained weight.14 While colonoscopy may reduce
the risk of subsequent cancer, the underlying lifestyle factors
that influence the development of new adenomas and other
obesity related conditions remain to be addressed.
The setting of colorectal cancer screening has been described
as an unexplored opportunity for endorsing changes in health
behaviours.15 Behaviour change programmes that target higher
risk groups may be more effective than those targeting the
population at large; thus adults who have been found to have
adenomas may be more motivated to engage with lifestyle
interventions.16 However, patients need to be aware of the
relevant risk factors and relate these to current personal
behaviours before the “teachable moment” opportunity can be
perceived as relevant. One study noted that while understanding
of the relation between smoking and lung cancer is shared and
accepted there is much less awareness of the relation between
colorectal cancer and lifestyle.17 These findings have been
echoed by other researchers, who found that patients with high
risk colorectal adenomas believed that their current behaviour
was appropriate or that they perceived no risk between health
behaviour and disease outcome.18 These authors suggest that
intervention programmes need to be tailored to individuals,
concentrate on the paucity of knowledge about the causes of
colon cancer in the general population, and highlight
motivational factors. In addition, the lack of advocacy on
lifestyle change in these settings may endorse poor health
behaviours as it is recognised that the absence of guidance may
produce a “health certificate effect” so that patients who receive
negative results may feel no need to modify their lifestyle.19
This situation may be particularly relevant for body weight,
where the lack of guidance to visibly obese patients may signal
lack of medical concern.
We evaluated the impact of a diet and physical activity
intervention programme (BeWEL) on bodyweight change in
overweight or obese people attending routine NHS colorectal
cancer screening clinics who had had colorectal adenomas
removed but were at risk of developing further obesity related
conditions.
Methods
The study was a multicentre, 1:1 parallel group randomised
controlled trial conducted in Scotland, United Kingdom from
November 2010 to May 2013. A detailed study protocol has
been published.20
Sample size
The sample size calculation was based on the primary outcome
of change in body weight at 12 months. A 7% weight loss at 12
months has been shown to be clinically effective in reducing
the risk of diabetes.21 Therefore to show a 7% weight loss with
80% power we estimated that 133 participants would be required
to complete each arm of the study (266 in total). Expected
recruitment rates and mean body weight at baseline (85.4 kg
(SD 17.3)) were based on a previous study in this population
subgroup, Bowel Health to Better Health.22 Thus, to achieve the
recruitment target we estimated that a pool of 558 patients would
be required from which to recruit, to allow for an expected
eligibility rate of 81% (n=452), a recruitment rate of 70%
(n=316), and a subsequent drop-out rate of 16% (n=266).
Participants and recruitment
We approached all screening participants in Tayside, Forth
Valley, and Ayrshire and Arran health boards between
November 2010 and April 2012 (and between January and April
2012 in Greater Glasgow and Clyde health board) who had a
diagnosis of adenoma confirmed by histopathology following
a positive faecal occult blood test result, as part of the national
bowel screening programme.
Eligible participants were those aged 50 to 74 years (in line with
the Scottish age criteria for routine colorectal cancer screening)
who had undergone polypectomy for adenoma, had a bodymass
index >25, and were able to undertake physical activity and
provide informed consent. Exclusion criteria were pregnancy,
insulin dependent diabetes mellitus, and any cancer diagnosis.
After screening colonoscopy, all patients received a letter
confirming the colonoscopy results. If an adenoma was
diagnosed, a letter from the lead consultant highlighting the
relation between lifestyle and adenoma recurrence and endorsing
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the BeWEL study was sent with the results. Two weeks later a
BeWEL invitation letter and brief information leaflet were sent
from the study team to potential participants. A research nurse
telephone screened those who responded positively and, if
eligible, posted them the full information leaflet and invited
them to the local study centre to provide written informed
consent and undergo baseline measures. At the end of this
meeting, all participants (intervention and control) were given
a copy of the British Heart Foundation booklet So You Want To
Lose Weight For Good.23
Baseline and follow-up measures
The study duration was 12 months. We recorded several
objective measures at baseline, three months, and 12 months:
height (cm), measured with a portable stadiometer (Leicester
height measure; Seca, Birmingham, UK); body weight (kg),
measured with the participant wearing indoor clothing and no
shoes, using a calibrated digital scale (Seca 877) waist
circumference (cm), measured with a measuring tape (Seca 201)
with the participant in the standing position and the tape
positioned midway between the lateral lower rib margin and
the iliac crest. If these landmarks could not be identified, the
measurement was taken at the level of the umbilicus. Two
measurements were taken after exhalation and the mean
recorded. Blood pressure was measured after the participant
had been seated for five minutes with the arm supported at heart
level, using an appropriately sized cuff on the left arm and a
digital blood pressure monitor (BP 3BTO;Microlife AG Swiss,
Widnau, Switzerland). We took two readings, or three if these
two were raised, one or more minutes apart, and reported the
mean.
Fasting blood samples were obtained by venepuncture and
analysed by standard techniques in the NHS laboratories to
evaluate levels of cholesterol (total, low density lipoprotein
cholesterol, and high density lipoprotein cholesterol),
triglycerides, glucose, glycated haemoglobin, and insulin. We
used homeostasis model assessment to assess insulin sensitivity
([insulin (µU/mL)×glucose (mmol/L)]/22.5).24
Physical activity levels were measured using a SenseWear
armband (BodyMedia, Pittsburgh, PA) worn on the upper arm
for seven days. This provided an objective and consistent
measure of daily energy expenditure, step count, and minutes
of moderate (3-5 metabolic equivalent of task, METs) and
vigorous (≥6 METs) activity.25
An interviewer administered questionnaire was used to record
self reported dietary intake and frequency of alcohol
consumption.
We used the dietary instrument for nutrition education
questionnaire to assign participants scores for fibre, fat, and
unsaturated fat.26 The fibre score (range 3-88) was based on the
frequency of intake of bread, rice, potatoes, pasta, and other
starchy foods, and fruit and vegetables (including beans and
lentils). A score of less than 30 (low) is equivalent to a fibre
intake of 20 g/day or less, whereas a score of more than 40
(high) is equivalent to an intake of more than 30 g/day. The fat
score (range 7->77) was based on intakes of foods that contribute
substantially to fat intake—that is, dairy foods, meat, processed
meat, fish, fried foods, sweet and savoury snacks, and fat
spreads. A score of less than 30 is equivalent to a fat intake of
83 g/day or less (<35% of total energy intake for an average
woman). The unsaturated fat score (range 3-12) was based on
the type of fats used, with a score of up to 5 considered low,
and a score of 10 or more considered high.
We used a modification of the Cappuccio and colleagues
two-item questionnaire27 to assess daily portions of fruit and
vegetables. Participants were asked “How many pieces of fruit
and vegetables (excluding potatoes) do you eat—of any sort—on
a typical day?” Fruit and vegetable portions were reported
separately, and fruit and vegetable juices were counted as a
maximum of one portion a day only. Portions sizes were
illustrated using show cards, as defined by NHS guidance on
portion size.28
Frequency of consumption of sugary drinks (excluding diet,
low calorie drinks and fresh fruit juice) were self reported using
nine frequency categories. To identify changes in frequency of
typical alcohol consumption (on week days and weekends) we
used questions from the alcohol use disorders inventory test.29
At baseline we collected sociodemographic data on age, sex,
ethnicity, marital status, education, employment, and area of
residence (to identify Scottish index of multiple deprivation30).
No information on medical history was collected, but we noted
current drug usage.
Randomisation
Following the baseline visit, eligible people who provided
consent were randomised 1:1 to receive either the diet and
physical activity intervention (BeWEL) or usual care. A
statistician, independent of the analysis of study outcomes, had
previously generated a randomisation list (site specific
identification numbers and group allocation) by using a
permuted block technique, with block sizes of four and eight,
stratified by trial site. This list was emailed to the study
administrator and trial manager. Research nurses allocated
participants a site specific identification number sequentially
and notified the study administrator on completion of baseline
measures for each participant. The study administrator then
identified the participant’s group allocation from the
randomisation list and notified the lifestyle counsellor of
participants allocated to the intervention group or sent the weight
loss booklet to participants allocated to usual care.
Blinding
The study team, including the research nurses, were blinded to
the participant’s group allocation until completion of the primary
outcome analysis. Exceptions were the trial manager, study
administrator, lifestyle counsellors, and participants who could
not be blinded owing to the nature of the intervention. None of
these unblinded staff had a role in data analysis.
Intervention group
Within two weeks of obtaining the baseline measures,
participants randomised to the intervention group participated
in the 12 month BeWEL programme. This was delivered by
trained lifestyle counsellors in three, one hour, one to one visits
during the first three months (including spouse or friend when
possible), followed by nine, monthly, 15 minute telephone
consultations. Thus each participant had a total of 5.25 hours
contact over a 12 month period. Motivational interviewing
techniques were utilised to explore self assessed confidence,
ambivalence, and personal values concerning weight change.31
All intervention participants were set a target goal of a 7%
reduction in body weight and provided with a personalised
energy prescription of 2508 kJ (600 kcal) below that required
for weight maintenance, and bodyweight scales for self
monitoring. No drugs were provided or promoted.
In the first face to face visit, a 24 hour recall of dietary intake
was undertaken to promote discussion around current food and
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drink intake and to allow counsellors to introduce the concept
of personalised dietary change. The components of the British
Heart Foundation booklet received at baseline were discussed
in detail in relation to the participant’s eating habits.23 Topics
covered caloric reduction through decreasing portion sizes and
reducing intakes of sugary drinks, alcohol, fast foods, snack
foods, and processed and red meat. Higher consumption of
fruits, vegetables, and whole grains were encouraged.
Counselling about personalised physical activity (according to
individual ability and disability) was guided by baseline data
and largely focused on brisk walking, with pedometers provided
for self monitoring.
Counsellors were encouraged to concentrate on one topic (diet
or physical activity) for the remainder of the first visit, on the
outstanding topic in the second visit, and to review progress
and revisit goals based on achievements to date at the final visit.
Participants were encouraged to identify specific behavioural
goals and make short term specific
“implementation-intentions.”32Telephone consultations focused
on support for making lifestyle changes drawing on recent
experience, checking progress, and discussing areas of success
and difficulty. Advice was given on relapse (as appropriate) and
support for restarting behavioural changes. Weight was self
monitored through the duration of the study, reported to the
counsellors, and feedback provided at each consultation. The
detailed intervention protocol for all intervention procedures
has been published elsewhere.33
Control group
Participants allocated to the control group after baseline
measures had been obtained received no further contact until
recall for three and 12 month follow-up measures.
Primary and secondary outcomes
The primary outcome was change in body weight at 12 months.
Secondary outcomes were percentage weight loss, waist
circumference, blood pressure, fasting cardiovascular biomarkers
(levels of total cholesterol, low density lipoprotein cholesterol,
high density lipoprotein cholesterol, and triglycerides), and
glucose metabolism variables (fasting plasma glucose, fasting
insulin, homeostasis model assessment, and glycated
haemoglobin). We also assessed health behaviours (dietary and
alcohol, and physical activity). We also analysed self reported
psychosocial variables (self efficacy, self assessed health and
quality of life, perceived risk factors for colorectal cancer,
perceived acceptability of the programme, and intervention
costs). The current paper reports the results of the primary
outcome and the objectively measured secondary outcomes of
eating and drinking habits.
Analysis
We used OpenClinica (www.OpenClinica.com) an open source,
Good Clinical Practice compliant system for data management.
In the primary analysis undertaken in randomised participants
we used an intention to treat analysis with all available data.
We carried out multiple linear regression analyses with mixed
effects models (allowing for heterogeneity in treatment effect
by site) adjusted for the corresponding baseline values (for
example, baseline weight for analysis of weight at follow-up),
with group allocation and site as fixed effects.
For the primary outcomewe also undertook a sensitivity analysis
that used both repeated measures and multiple imputations for
missing values (assuming data were missing at random). We
examined multiple imputations to ensure that data were missing
at random, then we ran and analysed 50 imputations together.
We compared the results with the primary analysis to assess the
impact of missing values. In addition, we carried out a
prespecified subgroup analysis for socioeconomic status using
fifths of Scottish index of multiple deprivation as an interaction
term.
We carried out a secondary analysis on blood variables (except
glycated haemoglobin) to exclude samples where participants
had reported eating less than 12 hours previously.
Logistic regression was used to compare the percentage of
randomised participants by group and time who achieved at
least 5% and 7% weight loss, and who reduced their intake of
alcohol and sugary drinks (in consumers only). Analyses
controlled for site and any other baseline characteristics
associated with the outcome. The data analysis was generated
using SAS software, version 9.3.
Results
Recruitment and follow-up
Of the 997 screening participants approached, 492 (49%)
expressed an interest in participation; 345 (35%) declined
participation and 160 (16%) did not respond (figure⇓). Of those
who responded positively, 108 had a body mass index of <25,
13 responded to postal invitations to take part after recruitment
to the study had closed, and 42 decided not to continue after
further considering the study. The remaining 329 were
randomised (163 to intervention, 166 to control). At three
months 314 (94% intervention, 97% control) participants had
completed the primary outcome measures, and 305 (91%
intervention, 95% control) completed the trial at 12 months
(93%).
Baseline characteristics
Participant’s ages ranged from 50 to 75 years (reflecting the
age for colorectal cancer screening in Scotland) (table 1⇓, see
supplementary table for baseline and clinical characteristics of
only those who completed the study). Almost half (n=155, 47%)
of the randomised participants had a body mass index in the
obese category (>30) and 47 (14%) reported a diagnosis of type
2 diabetes mellitus. Around half of the men (49%) and 79% of
the women reported having tried to lose weight previously.
Overall, 74% of the participants were men, and 35% lived in
the two most deprived Scottish index of multiple deprivation
fifths. The personal characteristics of the participants in each
group did not differ significantly.
Intervention delivery
Data from counsellor records showed that 97% of participants
in the intervention group attended all face to face consultations,
with 95% completing at least five of the nine planned telephone
calls and 59% completing all nine.
Primary outcome
Mean weight loss at 12 months in the intervention group was
3.50 kg (SD 4.91) (95% confidence interval 2.70 to 4.30 kg)
and in the control group was 0.78 kg (SD 3.77) (0.19 to 1.38
kg, table 2⇓). The primary analysis (with adjustment for site
and baseline body weight) showed a group difference in weight
loss of 2.70 kg (95% confidence interval 1.70 to 3.67 kg). After
multiple imputation to account for missing values, the estimated
difference in weight change between the two groups remained
significant at 2.69 kg (1.70 to 3.67 kg). Adding deprivation
status to the model had no effect on weight loss outcomes. It is
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notable that in the intervention group, weight loss continued
throughout the study, with maximum weight loss achieved at
12 months. Weight loss in the control group was modest in the
first three months and negligible thereafter.
Secondary outcomes
The mean percentage weight loss at 12 months in the
intervention group was 3.92% (SD 5.35%) (95% confidence
interval 3.05% to 4.78%) compared with 0.83% (SD 4.10%)
(0.18% to 1.47%) in the control group. The group difference
was 3.04% (95% confidence interval 2.16% to 3.92%). The
proportion of participants who lost 5% body weight was
significantly higher in the intervention group than in the control
group (36% v 12%), with the intervention group showing a
relative risk of achieving 5% weight loss (compared with the
control group) of 3.12 (95% confidence interval 1.92 to 5.07).
The proportion of participants who achieved the target of 7%
weight reduction was also higher in the intervention group (22%
v 9%, relative risk 2.5, 95% confidence interval 1.40 to 4.48).
Significantly greater reductions in waist circumference and body
mass index were also detected in the intervention group than in
the control group at three and 12months (table 2). At 12months,
the intervention group showed a significantly greater decrease
in both diastolic and systolic blood pressure and blood glucose
measures (table 3⇓). A weak improvement in glycated
haemoglobin percentage was also noted at 12 months, although
this difference did not reach significance (P=0.058).
Statistically significant between group differences were also
detected for changes in both physical activity and dietary habits
(table 4⇓). At three and 12 months the average step count had
increased in the intervention group and decreased in the control
group, resulting in a significant between group difference of
694 steps a day at 12 months. At 12 months the intervention
group showed an increased time being active overall (notably
in moderate activity) and by a significantly greater amount than
the control group, which had become less active. The fat scores
indicate a significantly greater decrease in frequency of
consumption of high fat foods in the intervention group than in
the control group at three and 12 months. Significant group
differences were detected in the change in fibre score at three
months, but this was not maintained at 12 months. However,
reported mean fruit and vegetable intake increased in the
intervention group to five portions a day at three and 12 months,
a significantly greater change than in the control group. The
proportion of participants achieving the five a day
recommendation in the intervention group increased from 61%
at baseline to 81% at three months and 73% at 12 months, an
increase that was greater than that in the control group (48% to
51% and 51%, respectively).
The majority of participants reported consuming sugary drinks
less than once a month (83% intervention group, 81% control
group). However, of those who consumed sugary drinks more
often, the odds of a reduction in intake at three months were
significantly lower in the control group (odds ratio 0.12, 95%
confidence interval 0.02 to 0.65, table 5⇓). By 12 months the
proportion of participants in the intervention group who had
reduced their intake remained high, at 82%, but the group
difference was no longer significant.
Alcohol was commonly consumed (by 86%), and most of these
participants maintained both the frequency and the amount they
consumed over the course of the study (table 5). At three
months, more of the participants in the intervention group (33%)
than in the control group (22%) had reduced their frequency of
consumption, a group difference that was not maintained at 12
months. When considering the amount of alcohol consumed
(rather than the frequency), more of the intervention group had
significantly reduced their intake on weekdays (45% v 30%;
odds ratio 0.50, 95% confidence interval 0.26 to 0.95), but no
group differences were noted for weekend consumption.
The average total intervention cost per participant (n=163) was
£546 ($914; €662) and the average cost per participant who
completed the intervention (n=148) was £601.
The cost per participant consisted of intervention related
literature and equipment (£38); lifestyle counsellors’ face to
face contact time for up to three visits (£134); travel costs,
including staff time (£177); and costs not directly allocated to
participants (£197). The last category included staff time
required for administrative activities, which are often ignored
in the costing of interventions. The travel costs and
administrative costs incurred might be higher in this research
study than they would be in routine practice.
Contact cost per participant was higher for the first meeting
(£63 (SD £30.53)) than for subsequent meetings (£40 (SD
£20.42) and £38 (SD £20.51)) with considerable variation across
participants.
Adverse events
No adverse events reported by participants were considered to
be related to participation in the trial.
Discussion
A 12 month, personalised, behaviourally focused weight loss
programme is associated with sustained changes in bodyweight,
physical activity, and eating and drinking habits in older adults.
The average percentage weight loss was 3.9% in the intervention
group, with over a third of participants achieving the clinically
relevant goal of 5%weight loss, and almost a quarter achieving
the programme target of 7% weight loss. These changes were
accompanied by a decrease in fat intake and an increase in fruit
and vegetable consumption and physical activity.
Strengths and weaknesses of this study
Lifestyle interventions in screening settings will only reach
people who choose to participate, with those from less affluent
areas generally being under-represented. However, a strength
of this study is that the participants came from a range of
sociodemographic backgrounds, and this variable had no effect
on weight loss outcomes. The proportion of men in this trial
(76%) was much higher than in other weight loss trials in older
adults.34 However, this is in keeping with the population
presenting for colonoscopy as a result of faecal occult blood
screening,35 suggesting that the screening setting provides an
opportunity to engage with men, who are generally considered
“hard to reach.” Indeed, 51% of the men in this study reported
never having tried to lose weight previously. The continued
weight loss at 12 months in the intervention participants
indicates an important effect of continued (telephone) support.
A weakness of the study (indeed of any study that cannot use
routinely collected data) was the need for repeat measurements
of body weight in the control group (to measure the primary
outcome), which may itself have been enough to increase
awareness of weight change and motivated some degree of
weight management. The weight loss seen in the control group
ran contrary to usual patterns of weight gain (which can reach
400 g a year),36 and it is impossible to disentangle the effect of
study measurement procedures from study care procedures
(booklet on weight loss, introductory letter from the consultant
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that highlighted the association between lifestyle and adenoma
recurrence).
Strengths and weakness in relation to other
studies
Our findings compare favourably with other weight loss
programmes of diet and activity advice in older adults, which
generally achieve modest (3%) weight loss up to six months,
followed by weight maintenance or gain.34 In contrast, the
current programme produced continued weight reduction
throughout the 12 month period with telephone support. Weight
loss was less than that achieved by the more intensive Diabetes
Prevention Research Group study, where 58% of participants
achieved 5% or more weight loss, but such programmes may
be less feasible in routine clinical practice.10Recent randomised
controlled trials of non-drug related weight loss have highlighted
the effectiveness of commercially run group programmes, which
typically necessitate major input by participants (for example,
one hour a week for 12 weeks).37 These have generally shown
greater success than one to one programmes, but our findings
show that similar results can be achieved with individualised
counselling alone with considerably less participant contact and
much higher retention rates. In a systematic review of weight
loss in obese older adults, the drop-out rates for group
programmes of diet and exercise (without individual
counselling) were 11-20%.38 In a primary care based group
programme, drop out was reported to be 55%.34 Our retention
rate of 93% compares favourably with these studies.
Meaning of the study: implications for
clinicians and policy makers
Weightmanagement programmes in secondary care are common
in the context of diabetes but do not feature in the cancer
screening setting. In the Scottish screening programme, 2.7%
(n=11 036) of participants have positive faecal occult blood test
results, and, of these, 32% have adenomas, which translates to
around 3500 people in Scotland having a diagnosis of adenoma
each year through the programme.39
Discussing weight in the context of colorectal cancer screening
is justified as obesity is a reported risk factor for recurrence of
colorectal adenomas, particularly in men. It is notable that the
Scottish health survey reports that 80% of Scottish men and
almost 70% of Scottish women aged 55 to 74 are overweight
or obese.40
Current evidence does not suggest that an adenoma diagnosis
in itself is associated with change in health behaviours.41 The
current findings provide an important and relevant evidence
base that highlights the potential benefits of weight loss for
prevention of all obesity related cancers (including breast,
endometrial, and oesophageal) at a life stage where fear of
cancer is high and particularly in those in whom an increased
risk of disease has been identified.42
Although there is widespread recognition that health promotion
is central to the provision of healthcare,43 the potential for
healthcare systems (including hospitals and clinics) to promote
appropriate diet, physical activity, and body weight is an area
that is underdeveloped.44 Recent initiatives such as the “health
promoting health service” and “every contact counts” in the
United Kingdommay provide opportunities to deliver screening
and prevention programmes.45 46
Unanswered questions and future research
A full cost benefit analysis is still to be undertaken. Further
research is required to explore whether behaviour change and
weight loss is continued beyond the intervention and to assess
the impact of a fully powered, long term programme on
colorectal adenomas and other obesity related comorbidities.
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Tables
Table 1| Baseline and clinical characteristics at randomisation. Values are numbers (percentages) unless stated otherwise
Total (n=329)Control group (n=166)Intervention group (n=163)Characteristics
63.6 (6.8), 50-7563.6 (6.7), 50-7563.5 (7.0), 50-75Age (years), mean (SD), range
243 (74)123 (74)120 (74)Men
Marital status:
21 (6)14 (8)7 (4)Single
262 (80)132 (80)130 (80)Married or cohabiting
46 (14)20 (12)26 (16)Divorced, widowed, or separated
Ethnicity:
327 (99)164 (99)163 (100)White
1 (0.3)1 (1)0 (0)Asian or Asian British
1 (0.3)1 (1)0 (0)Other
Highest educational qualification:
3 (1)2 (1)1 (1)Primary school
128 (39)65 (39)63 (39)Secondary school
153 (47)77 (46)76 (47)Other professional or technical qualification after school
45 (14)22 (13)23 (14)University or postgraduate degrees
Employment status:
187 (57)97 (58)90 (55)Retired
86 (26)41 (25)45 (28)Employed full time
32 (10)14 (8)18 (11)Employed part time
12 (4)10 (6)2 (1)Unemployed
12 (4)4 (2)8 (5)Other
Scottish index of multiple deprivation (fifths):
54 (16)29 (18)25 (15)1 (most deprived)
61 (19)28 (17)33 (20)2
59 (18)33 (20)26 (16)3
84 (26)45 (27)39 (24)4
71 (22)31 (19)40 (25)5 (least deprived)
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Table 2| Changes in anthropometric measures from baseline to three and 12months, by treatment group. Values aremeans (95% confidence
intervals) unless stated otherwise
Between group differences*, P
value
Control groupIntervention groupBaseline and follow-up
measures Difference to baselineMean (SD)NoDifference to baselineMean (SD)No
Body weight (kg):
——88.4 (14.3)166—90.2 (14.9)163Baseline
1.42 (0.84 to 1.99), <0.001–0.67 (–1.00 to –0.34)88.1 (14.2)161–2.10 (–2.57 to –1.63)88.7 (15.0)1533 months
2.69 (1.70 to 3.67), <0.001–0.78 (–1.38 to –0.19)88.1 (14.2)157–3.50 (–4.30 to –2.71)87.2 (15.7)14812 months
Body mass index†:
——30.4 (3.9)166—31.0 (4.5)163Baseline
0.48 (0.20 to 0.75), 0.0007–0.23 (–0.34 to –0.11)30.2 (4.0)161–0.72 (–0.89 to –0.56)30.4 (4.6)1533 months
0.92 (0.64 to –1.20), <0.001–0.27 (–0.47 to –0.07)30.1 (3.8)157–1.22 (–1.50 to –0.94)29.9 (4.8)14812 months
Waist circumference (cm):
——103.9 (10.9)166—104.7 (10.9)163Baseline
1.17 (0.25 to 2.10), 0.015–1.34 (–1.82 to –0.87)102.7 (11.1)159–2.55 (–3.14 to –1.97)102.6 (11.1)1533 months
2.68 (1.74 to 3.62), <0.001–2.16 (–2.85 to –1.47)102.1 (11.1)157–4.91 (–5.79 to –4.03)100.2 (12.0)14512 months
*Adjusted for baseline value and site.
†Defined as (weight (kg)/height (m)2).
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Table 3| Changes in cardiovascular risk and glucose metabolism biomarkers (secondary analyses). Values are means (95% confidence
intervals) unless stated otherwise
Between group differences, P value12 months3 monthsBaseline
Measures 12 months*3 months*Mean (SD)NoMean (SD)NoMean (SD)No
Systolic blood pressure (mm Hg):
3.8 (0.9 to 6.7),
0.011
1.3 (–1.6 to 4.2),
0.365
138 (17.8)148139 (17.7)153143 (17.3)163Intervention
142 (17.5)155139 (16.7)160142 (18.2)166Control
Diastolic blood pressure (mm Hg):
1.8 (0.2 to 3.3),
0.031
1.8 (0.2 to 3.3),
0.027
81 (9.7)14882 (9.9)15384 (9.6)163Intervention
83 (9.6)15583 (9.4)16084 (10.3)166Control
Total cholesterol (mmol/L):
0.10 (–0.07 to 0.27),
0.234
0.04 (–0.13 to 0.21),
0.624
4.83 (1.06)1254.94 (1.21)1265.17 (1.23)144Intervention
4.92 (1.17)1314.90 (1.14)1355.12 (1.22)150Control
HDL cholesterol (mmol/L):
–0.02 (–0.07 to
0.03), 0.466
0.01 (–0.05 to 0.06),
0.808
1.37 (0.34)1251.32 (0.33)1261.36 (0.36)144Intervention
1.37 (0.39)1311.37 (0.43)1351.36 (0.39)150Control
LDL cholesterol (mmol/L):
0.11 (–0.04 to 0.26),
0.160
0.06 (–0.09 to 0.21),
0.459
2.76 (0.92)1242.86 (1.04)1223.05 (1.07)141Intervention
2.80 (1.04)1292.81 (1.03)1332.97 (1.07)147Control
Triglycerides (mmol/L):
0.04 (–0.12 to 0.20),
0.591
–0.05 (–0.21 to
0.11), 0.568
1.51 (0.87)1251.69 (1.20)1261.70 (1.13)144Intervention
1.66 (1.02)1311.65 (1.00)1351.78 (1.11)150Control
Glucose (mmol/L):
0.27 (0·01 to 0.54),
0.045
0.29 (0.03 to 0.56),
0.031
5.68 (1.38)1255.74 (1.57)1276.11 (2.02)142Intervention
6.08 (1.67)1326.11 (2.06)1346.12 (1.93)149Control
Insulin (mmol/L):
–0.32 (–3.02 to
2.39), 0.818
–0.36 (–2.93 to
2.21), 0.784
12.77 (11.05)7411.41 (12.50)8811.12 (8.27)104Intervention
13.48 (10.21)7910.60 (9.67)9010.17 (8.82)110Control
Homeostasis model assessment:
0.43 (–0.62 to 1.48),
0.422
–0.32 (–1.31 to
0.67), 0.521
3.29 (3.16)743.42 (5.57)883.25 (3.10)103Intervention
3.72 (3.18)792.91 (3.14)902.81 (2.79)109Control
Glycated haemoglobin (%):
0.13 (–0.004 to
0.26), 0.058
0.05 (–0.08 to 0.18),
0.469
5.82 (0.75)1235.98 (1.18)1266.02 (1.17)149Intervention
6.03 (0.96)1306.08 (1.21)1356.03 (1.07)151Control
HDL=high density lipoprotein cholesterol; LDL=low density lipoprotein cholesterol.
*Adjusted for baseline value and site.
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Table 4| Changes in dietary intake and physical activity. Values are means (95% confidence intervals) unless stated otherwise
Between group differences, P value12 months3 monthsBaseline
Measures 12 months*3 months*Mean (SD)NoMean (SD)NoMean (SD)No
Daily average physical activity
Time spent active (mins):
–12.9 (–23.8 to –1.9),
0.021
–3.7 (–14.5 to 7.1), 0.50089 (65.3)14088 (56.6)14582 (62.3)156Intervention
74 (62.0)14880 (62.4)15079 (55.9)157Control
Time spent in sedentary activity (mins):
17.1 (–15.8 to 50.0),
0.308
3.5 (–29.3 to 36.2), 0.8351275 (175.5)1371274 (141.5)1411287 (130.6)153Intervention
1296 (155.1)1441296 (136.2)1441299 (144.8)153Control
Time spent in moderate activity (mins):
–10.9 (–21.7 to –0.1),
0.047
–5.6 (–16.3 to 5.1), 0.30586 (63.4)13787 (54.9)14181 (58.0)153Intervention
73 (60.7)14478 (60.6)14477 (53.7)153Control
Time spent in vigorous activity (mins)
0.3 (–0.6 to 1.3), 0.53–0.05 (–1.0 to 0.9), 0.9151 (3.0)1372 (3.2)1412 (11.3)153Intervention
2 (4.9)1442 (4.5)1442 (4.3)153Control
Step count:
–694 (–1321 to –67),
0.030
–619 (–1241 to 3), 0.0518697 (4404)1408994 (4430)1458429 (3995)156Intervention
7460 (3873)1487753 (3833)1507734 (3538)157Control
Dietary intake
Fat consumption score:
3.8 (2.1 to 5.6), <0.0014.6 (2.9 to 6.3), <0.00124 (7.4)14624 (8.5)15230 (10.6)163Intervention
28 (10.3)15629 (10.6)15932 (10.6)166Control
Unsaturated fat score:
–0.2 (–0.5 to 0.1), 0.154–0.2 (–0.5 to 0.1), 0.1179 (1.2)1479 (1.4)1529 (1.6)161Intervention
9 (1.5)1569 (1.7)1609 (1.7)165Control
Fibre food consumption score:
–0.4 (–2.3 to 1.4), 0.669–2.6 (–4.4 to –0.8), 0.00533 (10.4)14835 (10.6)15333 (10.0)163Intervention
32 (9.1)15732 (9.3)16132 (9.8)166Control
Fruit and vegetable (portion/day):
–0.8 (–1.2 to –0.3),
0.0004
–0.9 (–1.3 to –0.4),
<0.001
5 (2.4)1485 (2.2)1534 (2.2)163Intervention
4 (2.4)1574 (2.1)1614 (2.2)166Control
*Adjusted for baseline value and site.
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Table 5| Changes in sugary drink and alcohol consumption in consumers only. Values are odds ratios (95% confidence intervals) unless
stated otherwise
Between group differences, P value12 months3 months
Sugary drinks and alcohol
consumption 12 months*3 months*
No (%) with reduced
intakeNo
No (%) with reduced
intakeNo
Sugary drinks:
0.67 (0.14 to 3.20),
0.616
0.12 (0.02 to 0.65),
0.014
18 (82)2220 (87)23Intervention
21 (75)2816 (59)27Control
Alcohol:
Frequency:
0.64 (0.37 to 1.13),
0.124
0.56 (0.32 to 0.97),
0.039
38 (30)12844 (33)132Intervention
29 (21)13530 (22)138Control
Weekday consumption:
0.50 (0.26 to 0.95),
0.034
0.72 (0.38 to 1.37),
0.319
38 (45)8532 (36)88Intervention
27 (30)9028 (31)91Control
Weekend consumption:
1.32 (0.73 to 2.38),
0.363
0.97 (0.60 to 1.67),
0.904
27 (22)12437 (29)128Intervention
35 (27)12837 (28)131Control
*Adjusted for site and any other baseline characteristics associated with intake.
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Figure
Trial recruitment and retention
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